Participated · Series B · Oct 2025

BridGene Biosciences is a biotechnology company that leverages its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform to discover covalent small-molecule therapeutics against historically undruggable targets. Its lead candidate, BGC-515, is a covalent TEAD inhibitor now in clinical development for solid tumors and slated to progress into Phase 2 with the new funding. The company is also advancing a second, unnamed program expected to enter the clinic in 2027 and is building a broader pipeline across oncology and autoimmune diseases. BridGene plans to use its expanded resources to deepen strategic collaborations that further validate the versatility of its platform in oncology, immunology and neurology. While no revenue or patient metrics were disclosed, the firm emphasizes translating its chemical biology discoveries into transformative therapies. The latest financing underscores investor confidence in BridGene’s platform approach and clinical pipeline.

Participated · Series A · Sep 2025

Rapafusyn develops non-degrading macrocyclic molecular glues, branded RapaGlues, to address challenging therapeutic targets. Its platform includes DNA-encoded libraries (DELs) and arrayed libraries of RapaGlues that form neo-protein-protein interactions to inhibit target proteins. The compounds are rationally designed to bind FKBP and form ternary complexes with disease target proteins, enabling modulation of intricate protein-protein interactions. The platform’s modular architecture supports SAR and optimization for potency, selectivity, and physicochemical properties to accelerate drug discovery. RapaGlues frequently exhibit cell permeability from the starting point, enhancing their therapeutic potential. The company is led by President and CEO Dr. Sean Hu and intends to use new funding to expand operations and advance its development efforts. Rapafusyn Pharmaceuticals develops non-degrading macrocyclic molecular glues (RapaGlues™) designed to form neo-protein–protein interactions and inhibit target proteins by binding FKBP and creating ternary complexes. The company has built both DNA-encoded libraries (DELs) and arrayed libraries of RapaGlues™ to generate chemical starting points for difficult targets. Its modular architecture enables SAR and optimization for potency, selectivity, and physicochemical properties, and many starting points frequently exhibit cell permeability. Rapafusyn focuses on macrocyclic peptide-based RapaGlues™ as a platform approach to address challenging therapeutic targets. The company plans to use new funding to accelerate progress across its pipeline and to further enhance internal capabilities. Rapafusyn was founded by Jun O. Liu and is headquartered in Baltimore, MD.

Participated · Series A · Sep 2024

VerImmune is developing a virus-inspired particle (ViP™) platform that enables a first-in-class cancer immunotherapy approach called anti-tumor immune redirection (AIR). The AIR approach harnesses patients’ pre-existing immune memory from past infections or childhood vaccinations to redirect immune responses against tumors. The company’s primary focus is oncology, aiming to offer new treatment options for patients with limited responses to current therapies. Led by Founder and CEO Dr. Joshua Wang, VerImmune plans to use the financing to expand operations and advance development efforts of its ViP platform. The company recently strengthened its board with the additions of Dr. Che Hsu (General Manager of Beiley) and Dr. Marta New (CEO of Radyus Research) as an independent director. VerImmune is an early-stage biotechnology company based in Washington, DC, developing products from a novel Virus-inspired Particle (ViP™) technology platform. Its lead immuno-oncology candidate, VERI-101, uses the ViP platform to harness pre-existing cellular immune memory from prior cytomegalovirus (CMV) infection in an approach the company calls Anti-tumor Immune Redirection (AIR). AIR is positioned as a potential first-in-class cancer immunotherapy that could be used as a stand-alone treatment or in combination with other immunotherapies for patients with untreatable cancers or resistance to existing therapies. VerImmune plans to use the recent financing to accelerate GLP/GMP activities toward an IND for VERI-101. The company is led by founder and CEO Joshua Wang. Financially, VerImmune raised an additional $3.125 million from a follow-on Seed financing and a partnership milestone payment to support development and process activities. VerImmune is an early-stage biotechnology company developing a first-in-class cancer therapy called Anti-tumor Immune Redirection (AIR). The AIR strategy uses a proprietary virus-inspired particle (ViP) platform to redirect pre-existing pathogenic or childhood vaccine immune memory toward tumors. The company is led by CEO Joshua Wang and COO John Troyer. VerImmune plans to use the financing to accelerate its lead product development timelines and to grow its team. Founded in early 2020, the company operated near Johns Hopkins East Baltimore Campus and in early 2022 moved its research laboratories to Johnson & Johnson Innovation – JLABS @ Washington, DC. The company states its laboratory headquarters remain within the BioHealth Capital Region cluster.

Participated · Series A · Dec 2023

Cytonus Therapeutics is developing a proprietary Cargocyte™ Drug Delivery Platform—engineered, synthetic cell-like delivery vehicles designed to carry multiple therapeutic payloads into hard-to-reach tissues. The company has built a pipeline of proprietary immunotherapeutic products targeting cancers, infectious diseases, inflammatory diseases, and cognitive disorders. Cargocytes are described as programmable, off-the-shelf delivery drones that can selectively, potently, and controllably deliver well-validated therapies. Cytonus will use the funds from its recent financing to continue development of this portfolio and advance payload delivery to metastatic tumors and the central nervous system. The company is led by CEO Remo Moomiaie-Qajar, MD, with Chief Scientific Innovator Richard Klemke, PhD, and executive chairman Christopher Thorne, JD-MBA. In conjunction with the financing Cytonus expanded its board and scientific advisors, including additions of Jaeyeol (Jae) An, PhD, and John C. Bell, PhD.

Led · Series A · Aug 2023

DotBio is a Singapore-based biopharmaceutical company developing multi-functional and intracellular antibody therapies for immuno-oncology using its proprietary DotBody platform. The company combines its modular DotBody technology with CoFi and Hot-CoFi stabilization technologies, high-throughput miniaturized assays and data analytics to rapidly prototype multi-functional antibodies. Its platform is designed to generate therapeutic molecules that target both extracellular and intracellular disease drivers and to screen thousands of multi-functional antibody prototypes. DotBio is led by CEO Ignacio Asial. The company recently closed a USD 5.6M Pre-Series A financing to support its near-term plans. It intends to use the funds to commence pre-clinical studies (including animal efficacy and CMC studies) and to scale its DotBody platform ahead of future clinical development.